The Locally Advanced Nonmetastatic Cancer

  • Florence Huguet
Part of the Medical Radiology book series (MEDRAD)


At the time of diagnosis, around 20% of patients present with a resectable tumor, 50% with a metastatic disease, and 30% with a locally advanced tumor, unresectable because of superior mesenteric artery (SMA) or celiac encasement but nonmetastatic. Despite advances in chemoradiation (CRT) and improved systemic chemotherapeutic agents, those who present with locally advanced disease suffer both from high rates of distant metastatic failure and local progression, with median survival time ranging from 5 to 11 months. In the past 30 years, modest improvements in median survival have been attained for patients with locally advanced tumors treated by CRT or chemotherapy (CT) protocols. However, no significant impact on long-term survival has been accomplished. Optimal therapy for patients with locally advanced pancreatic carcinoma remains controversial. A recent systematic review concluded that there is no standard for the treatment of locally advanced pancreatic cancers, but two options: gemcitabine-based CT or CRT. These approaches are complementary and both should be considered. An induction CT followed by a CRT for nonprogressive patients is a promising strategy whose validation is ongoing in a phase III trial.


Pancreatic Cancer Plane Target Volume Maximal Tolerate Dose External Beam Radiation Therapy Stereotactic Body Radiation Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Andre T, Balosso J et al (2000) Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: results of a feasibility study. Int J Radiat Oncol Biol Phys 46:903–911PubMedCrossRefGoogle Scholar
  2. Ben-Josef E, Shields AF, Vaishampayan U, Vaitkevicius V, El-Rayes BF, McDermott P, Burmeister J, Bossenberger T, Philip PA (2004) Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int J Radiat Oncol Biol Phys 59:454–459PubMedCrossRefGoogle Scholar
  3. Boz G, De Paoli A, Innocente R, Rossi C, Tosolini G, Pederzoli P, Talamini R, Trovo MG (2001) Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma. Int J Radiat Oncol Biol Phys 51:736–740PubMedCrossRefGoogle Scholar
  4. Brown MW, Ning H, Arora B, Albert PS, Poggi M, Camphausen K, Citrin D (2006) A dosimetric analysis of dose escalation using two intensity-modulated radiation therapy techniques in locally advanced pancreatic carcinoma. Int J Radiat Oncol Biol Phys 65:274–283PubMedCrossRefGoogle Scholar
  5. Burris HA III, Moore MJ et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413PubMedGoogle Scholar
  6. Chauffert B, Mornex F et al (2008) Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 19:1592–1599PubMedCrossRefGoogle Scholar
  7. Chung HW, Bang SM, Park SW, Chung JB, Kang JK, Kim JW, Seong JS, Lee WJ, Song SY (2004) A prospective randomized study of gemcitabine with doxifluridine versus paclitaxel with doxifluridine in concurrent chemoradiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 60:1494–1501PubMedCrossRefGoogle Scholar
  8. Cohen SJ, Dobelbower R Jr, Lipsitz S, Catalano PJ, Sischy B, Smith TJ, Haller DG (2005) A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys 62:1345–1350PubMedCrossRefGoogle Scholar
  9. Crane CH, Antolak JA et al (2001) Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head. Int J Gastrointest Cancer 30:123–132PubMedCrossRefGoogle Scholar
  10. Crane CH, Abbruzzese JL et al (2002) Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 52:1293–1302PubMedCrossRefGoogle Scholar
  11. Crane CH, Ellis LM et al (2006) Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 24:1145–1151PubMedCrossRefGoogle Scholar
  12. Crane CH, Winter K, Regine WF, Safran H, Rich TA, Curran W, Wolff RA, Willett CG (2009) Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol 27:4096–4102PubMedCentralPubMedCrossRefGoogle Scholar
  13. De Paoli A, Chiara S et al (2006) Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. Ann Oncol 17:246–251PubMedCrossRefGoogle Scholar
  14. Duffy A, Kortmansky J, Schwartz GK, Capanu M, Puleio S, Minsky B, Saltz L, Kelsen DP, O’Reilly EM (2008) A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann Oncol 19:86–91PubMedCrossRefGoogle Scholar
  15. Earle JD, Foley JF, Wieand HS, Kvols LK, McKenna PJ, Krook JE, Tschetter LK, Schutt AJ, Twito DI (1994) Evaluation of external-beam radiation therapy plus 5-fluorouracil (5-FU) versus external-beam radiation therapy plus hycanthone (HYC) in confined, unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 28:207–211PubMedCrossRefGoogle Scholar
  16. El-Rayes BF, Zalupski MM, Shields AF, Vaishampayan U, Heilbrun LK, Jain V, Adsay V, Day J, Philip PA (2003) Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer. J Clin Oncol 21:2920–2925PubMedCrossRefGoogle Scholar
  17. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z, Kolesnick R (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300:1155–1159PubMedCrossRefGoogle Scholar
  18. Gastrointestinal Tumor Study Group (1985) Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Cancer 56:2563–2568CrossRefGoogle Scholar
  19. Gastrointestinal Tumor Study Group (1988) Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 80:751–755CrossRefGoogle Scholar
  20. Goldstein D, Van Hazel G et al (2007) Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer. Br J Cancer 97:464–471PubMedCentralPubMedCrossRefGoogle Scholar
  21. Gorski DH, Beckett MA et al (1999) Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59:3374–3378PubMedGoogle Scholar
  22. Hazel JJ, Thirlwell MP, Huggins M, Maksymiuk A, MacFarlane JK (1981) Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial. J Can Assoc Radiol 32:164–165PubMedGoogle Scholar
  23. Heinemann V, Quietzsch D et al (2006) Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24:3946–3952PubMedCrossRefGoogle Scholar
  24. Hoyer M, Roed H et al (2005) Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol 76:48–53PubMedCrossRefGoogle Scholar
  25. Huguet F, Andre T et al (2007) Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25:326–331PubMedCrossRefGoogle Scholar
  26. Huguet F, Girard N, Guerche CS, Hennequin C, Mornex F, Azria D (2009) Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 27:2269–2277PubMedCrossRefGoogle Scholar
  27. Iannitti D, Dipetrillo T et al (2005) Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. Am J Clin Oncol 28:570–575PubMedCrossRefGoogle Scholar
  28. Ishii H, Okada S et al (1997) Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 79:1516–1520PubMedCrossRefGoogle Scholar
  29. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62PubMedCrossRefGoogle Scholar
  30. Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG (1985) Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil–an Eastern Cooperative Oncology Group study. J Clin Oncol 3:373–378PubMedGoogle Scholar
  31. Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA (2007) A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 68:809–816PubMedCrossRefGoogle Scholar
  32. Koong AC, Le QT et al (2004) Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 58:1017–1021PubMedCrossRefGoogle Scholar
  33. Koong AC, Christofferson E et al (2005) Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 63:320–323PubMedCrossRefGoogle Scholar
  34. Krempien RC, Munter MW et al (2006) Phase II study evaluating trimodal therapy with cetuximab intensity modulated radiotherapy (IMRT) and gemcitabine for patients with locally advanced pancreatic cancer [ISRCTN56652283]. J Clin Oncol (Meeting Abstracts) 24:4100Google Scholar
  35. Krishnan S, Rana V et al (2007) Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 110:47–55PubMedCrossRefGoogle Scholar
  36. Leach SD, Lee JE, Charnsangavej C, Cleary KR, Lowy AM, Fenoglio CJ, Pisters PW, Evans DB (1998) Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg 85:611–617PubMedCrossRefGoogle Scholar
  37. Li CP, Chao Y, Chi KH, Chan WK, Teng HC, Lee RC, Chang FY, Lee SD, Yen SH (2003) Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 57:98–104PubMedCrossRefGoogle Scholar
  38. Loehrer PJ, Powell ME, Cardenes HR, Wagner L, Brell JM, Ramanathan RK, Crane CH, Alberts SR, Benson AB (2008) A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol (Meeting Abstracts) 26:4506Google Scholar
  39. Louvet C, Andre T et al (2001) Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM). Ann Oncol 12:675–679PubMedCrossRefGoogle Scholar
  40. Louvet C, Andre T et al (2002) Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 20:1512–1518PubMedCrossRefGoogle Scholar
  41. Louvet C, Labianca R et al (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509–3516PubMedCrossRefGoogle Scholar
  42. Milano MT, Chmura SJ, Garofalo MC, Rash C, Roeske JC, Connell PP, Kwon OH, Jani AB, Heimann R (2004) Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 59:445–453PubMedCrossRefGoogle Scholar
  43. Minn AY, Schellenberg D et al (2009) Pancreatic tumor motion on a single planning 4D-CT does not correlate with intrafraction tumor motion during treatment. Am J Clin Oncol 32:364–368PubMedCrossRefGoogle Scholar
  44. Moertel CG, Childs DS Jr, Reitemeier RJ, Colby MY Jr, Holbrook MA (1969) Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2:865–867PubMedCrossRefGoogle Scholar
  45. Moertel CG, Frytak S et al (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48:1705–1710PubMedCrossRefGoogle Scholar
  46. Moore MJ, Goldstein D et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase iii trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966. doi: 10.1200/JCO.2006.07.9525 PubMedCrossRefGoogle Scholar
  47. Murphy JD, Adusumilli S, Griffith KA, Ray ME, Zalupski MM, Lawrence TS, Ben-Josef E (2007) Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 68:801–808PubMedCrossRefGoogle Scholar
  48. O’Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG, Mayer RJ, Gunderson LL, Rich TA (1994) Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331:502–507PubMedCrossRefGoogle Scholar
  49. Pipas JM, Zaki B et al (2006) Cetuximab, intensity-modulated radiotherapy (IMRT), and twice-weekly gemcitabine for pancreatic adenocarcinoma. J Clin Oncol (Meeting Abstracts) 24:14056Google Scholar
  50. Poen JC, Collins HL et al (1998) Chemo-radiotherapy for localized pancreatic cancer: increased dose intensity and reduced acute toxicity with concomitant radiotherapy and protracted venous infusion 5-fluorouracil. Int J Radiat Oncol Biol Phys 40:93–99PubMedCrossRefGoogle Scholar
  51. Poplin E, Feng Y et al (2009) Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27:3778–3785PubMedCentralPubMedCrossRefGoogle Scholar
  52. Reni M, Passoni P, Panucci MG, Nicoletti R, Galli L, Balzano G, Zerbi A, Di Carlo V, Villa E (2001) Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. J Clin Oncol 19:2679–2686PubMedGoogle Scholar
  53. Rich TA, Lokich JJ, Chaffey JT (1985) A pilot study of protracted venous infusion of 5-fluorouracil and concomitant radiation therapy. J Clin Oncol 3:402–406PubMedGoogle Scholar
  54. Rich T, Harris J, Abrams R, Erickson B, Doherty M, Paradelo J, Small W Jr, Safran H, Wanebo HJ (2004a) Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. Am J Clin Oncol 27:51–56PubMedCrossRefGoogle Scholar
  55. Rich TA, Shepard RC, Mosley ST (2004b) Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 22:2214–2232PubMedCrossRefGoogle Scholar
  56. Rocha Lima CM, Green MR et al (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22:3776–3783PubMedCrossRefGoogle Scholar
  57. Roldan GE, Gunderson LL, Nagorney DM, Martin JK, Ilstrup DM, Holbrook MA, Kvols LK, McIlrath DC (1988) External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer. Cancer 61:1110–1116PubMedCrossRefGoogle Scholar
  58. Safran H, Akerman P, Cioffi W, Gaissert H, Joseph P, King T, Hesketh PJ, Wanebo H (1999) Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroesophageal junction. Semin Radiat Oncol 9:53–57PubMedGoogle Scholar
  59. Saif MW, Eloubeidi MA et al (2005) Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. J Clin Oncol 23:8679–8687PubMedCrossRefGoogle Scholar
  60. Schellenberg D, Goodman KA et al (2008) Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 72:678–686PubMedCrossRefGoogle Scholar
  61. Shinchi H, Takao S, Noma H, Matsuo Y, Mataki Y, Mori S, Aikou T (2002) Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 53:146–150PubMedCrossRefGoogle Scholar
  62. Stathopoulos GP, Mavroudis D et al (2001) Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 12:101–103PubMedCrossRefGoogle Scholar
  63. Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P (2007a) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 25:2607–2615PubMedCrossRefGoogle Scholar
  64. Sultana A, Tudur Smith C, Cunningham D, Starling N, Tait D, Neoptolemos JP, Ghaneh P (2007b) Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 96:1183–1190PubMedCentralPubMedCrossRefGoogle Scholar
  65. Vaishampayan UN, Ben-Josef E, Philip PA, Vaitkevicius VK, Du W, Levin KJ, Shields AF (2002) A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies. Int J Radiat Oncol Biol Phys 53:675–679PubMedCrossRefGoogle Scholar
  66. Van Cutsem E, van de Velde H et al (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430–1438PubMedCrossRefGoogle Scholar
  67. van der Geld YG, van Triest B, Verbakel WF, van Sornsen de Koste JR, Senan S, Slotman BJ, Lagerwaard FJ (2008) Evaluation of four-dimensional computed tomography-based intensity-modulated and respiratory-gated radiotherapy techniques for pancreatic carcinoma. Int J Radiat Oncol Biol Phys 72:1215–1220Google Scholar
  68. Whittington R, Solin L, Mohiuddin M, Cantor RI, Rosato FE, Biermann WA, Weiss SM, Pajak TF (1984) Multimodality therapy of localized unresectable pancreatic adenocarcinoma. Cancer 54:1991–1998PubMedCrossRefGoogle Scholar
  69. Whittington R, Neuberg D, Tester WJ, Benson AB 3rd, Haller DG (1995) Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: a phase I Eastern Cooperative Oncology Group Trial. J Clin Oncol 13:227–232PubMedGoogle Scholar
  70. Wilkowski R, Rau H, Bruns C, Wagner A, Sauer R, Hohenberger W, Koelbl O, Heinemann V (2006) Randomized phase II trial comparing gemcitabine/cisplatin-based chemoradiotherapy (CRT) to 5-FU-based CRT in patients with locally advanced pancreatic cancer. J Clin Oncol (Meeting Abstracts) 24:4038Google Scholar
  71. Willett CG, Del Castillo CF et al (2005) Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer. Ann Surg 241:295–299PubMedCentralPubMedCrossRefGoogle Scholar
  72. Yeo TP, Hruban RH et al (2002) Pancreatic cancer. Curr Probl Cancer 26:176–275PubMedCrossRefGoogle Scholar
  73. Yip D, Karapetis C, Strickland A, Steer CB, Goldstein D (2007) Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Library 4:1–72Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  1. 1.Service d’Oncologie RadiothérapieHôpital Tenon, Assistance Publique – Hôpitaux de ParisParisFrance

Personalised recommendations